These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31998717)

  • 1. Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury.
    Bader M; Li Y; Tweedie D; Shlobin NA; Bernstein A; Rubovitch V; Tovar-Y-Romo LB; DiMarchi RD; Hoffer BJ; Greig NH; Pick CG
    Front Cell Dev Biol; 2019; 7():356. PubMed ID: 31998717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel GLP-1R/GIPR co-agonist "twincretin" is neuroprotective in cell and rodent models of mild traumatic brain injury.
    Tamargo IA; Bader M; Li Y; Yu SJ; Wang Y; Talbot K; DiMarchi RD; Pick CG; Greig NH
    Exp Neurol; 2017 Feb; 288():176-186. PubMed ID: 27845037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice.
    Li Y; Bader M; Tamargo I; Rubovitch V; Tweedie D; Pick CG; Greig NH
    J Neurochem; 2015 Dec; 135(6):1203-1217. PubMed ID: 25982185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose-Dependent Insulinotropic Polypeptide Ameliorates Mild Traumatic Brain Injury-Induced Cognitive and Sensorimotor Deficits and Neuroinflammation in Rats.
    Yu YW; Hsieh TH; Chen KY; Wu JC; Hoffer BJ; Greig NH; Li Y; Lai JH; Chang CF; Lin JW; Chen YH; Yang LY; Chiang YH
    J Neurotrauma; 2016 Nov; 33(22):2044-2054. PubMed ID: 26972789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice.
    Rachmany L; Tweedie D; Li Y; Rubovitch V; Holloway HW; Miller J; Hoffer BJ; Greig NH; Pick CG
    Age (Dordr); 2013 Oct; 35(5):1621-36. PubMed ID: 22892942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury.
    Li Y; Glotfelty EJ; Namdar I; Tweedie D; Olson L; Hoffer BJ; DiMarchi RD; Pick CG; Greig NH
    Exp Neurol; 2020 Feb; 324():113113. PubMed ID: 31730763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer's disease challenged mice.
    Lecca D; Bader M; Tweedie D; Hoffman AF; Jung YJ; Hsueh SC; Hoffer BJ; Becker RE; Pick CG; Lupica CR; Greig NH
    Neurobiol Dis; 2019 Oct; 130():104528. PubMed ID: 31295555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors.
    Spielman LJ; Gibson DL; Klegeris A
    Eur J Cell Biol; 2017 May; 96(3):240-253. PubMed ID: 28336086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
    Ji C; Xue GF; Lijun C; Feng P; Li D; Li L; Li G; Hölscher C
    Brain Res; 2016 Mar; 1634():1-11. PubMed ID: 26453833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
    Yuan Z; Li D; Feng P; Xue G; Ji C; Li G; Hölscher C
    Eur J Pharmacol; 2017 Oct; 812():82-90. PubMed ID: 28666800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
    Salles GN; Calió ML; Hölscher C; Pacheco-Soares C; Porcionatto M; Lobo AO
    Neuropharmacology; 2020 Jan; 162():107813. PubMed ID: 31628935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury.
    Bader M; Li Y; Lecca D; Rubovitch V; Tweedie D; Glotfelty E; Rachmany L; Kim HK; Choi HI; Hoffer BJ; Pick CG; Greig NH; Kim DS
    Neurobiol Dis; 2019 Apr; 124():439-453. PubMed ID: 30471415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
    Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
    Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.
    Mayendraraj A; Rosenkilde MM; Gasbjerg LS
    Peptides; 2022 May; 151():170749. PubMed ID: 35065096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives.
    Ferrari F; Moretti A; Villa RF
    Pharmacol Ther; 2022 Nov; 239():108277. PubMed ID: 36064147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
    Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
    Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
    Hansotia T; Drucker DJ
    Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury.
    Glotfelty EJ; Delgado T; Tovar-Y-Romo LB; Luo Y; Hoffer B; Olson L; Karlsson T; Mattson MP; Harvey B; Tweedie D; Li Y; Greig NH
    ACS Pharmacol Transl Sci; 2019 Apr; 2(2):66-91. PubMed ID: 31396586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.